FORT WORTH, Texas--(BUSINESS WIRE)--April 25, 2005--Alcon, Inc., (NYSE:ACL) announced the launch of the AcrySof(R) ReSTOR(R) Intraocular Lens (IOL) at a press conference during the American Society of ...

Slit lamp photo of the ReStor IOL in the eye. (All images courtesy of Francesco Carones, MD.) BARCELONA – The apodized optic design of the pseudoaccomodative Alcon AcrySof ReStor IOL may overcome the ...

Basel, March 23, 2017 - Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof® IQ ReSTOR® +2.5 ...

Basel, Switzerland, April 16, 2015-Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof® IQ ReSTOR® ...

April 15, 2005 — The U.S. Food and Drug Administration (FDA) has approved a rechargeable neurostimulation system to aid in the management of chronic intractable pain of the trunk and/or limbs; a dural ...

Please provide your email address to receive an email when new articles are posted on . MILAN — Alcon announced the launch of the AcrySof IQ ReSTOR +2.5 D and the AcrySof IQ ReSTOR multifocal toric +2 ...

SAN FRANCISCO (MarketWatch) -- Alcon Inc. said Wednesday after the closing bell that the Food and Drug Administration has granted approval for its intraocular lens, AcrySof ReSTOR, to be used by ...

Alcon, Inc. is the world's leading eye care company with sales of $4.4 billion in 2005. Alcon, which has been dedicated to the ophthalmic industry for more than 60 years, develops, manufactures and ...

The unique optical design of the ACTIVEFOCUS (TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses This ...

Novartis International AG / Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS design for uncompromised distance vision and presbyopia correction .